Todd Haim, PhD
CHIEF, OFFICE OF SMALL BUSINESS RESEARCH, NIH/NIA
Bethesda, Maryland, United States
Dr. Todd Haim was appointed Chief of the Office of Small Business Research at National Institute on Aging (NIA) in late 2018. He oversees the development and evolution of this exciting new office with the goal of improving both the quantity and quality of the SBIR/STTR applications. His previous position was Program Director at the National Cancer Institute’s SBIR Development Center, where he evaluated and managed SBIR & STTR grants and contracts focused on the development of novel cancer therapeutics, preventative agents, and drug discovery technologies. At NCI, Todd played a key role in the planning, design, and leadership of several center initiatives, including serving as coordinator of the NCI Investor Forum, helping to implement relevant workshops, draft targeted solicitations, and facilitate external partnerships. Prior to starting in the SBIR Development Center, he was a Research Associate and Christine Mirzayan Science and Technology Policy Fellow at the National Academy of Sciences. Dr. Haim staffed the Committee on Science, Engineering and Public Policy (COSEPUP) and his efforts centered on follow-up activities to the 2005 “Rising Above the Gathering Storm” report related to various innovation initiatives and evaluation programs. Previously, he completed a postdoctoral fellowship at Pfizer in which he actively led Pfizer’s research efforts in a collaboration with Washington University School of Medicine in St. Louis that illustrated a mechanism for altered cardiac contractility due to excess fatty acids. Dr. Haim graduated from Albert Einstein College of Medicine in January 2007 with a PhD in biomedical research and obtained a certificate in technology commercialization from John Hopkins’ Carey Business School in 2011. He has received several prestigious awards and honors including the 2014 NCI Leadership Development Award, a 2014 and 2017 NIH Director’s Award and the NJ Governor’s Award for Volunteerism in the Field of Health.
12:00 PM - 12:55 PM
Monday, June 8
Brave Innovations: Public and Private Solutions to Advance Alzheimer’s Therapeutics and Diagnostic in a Risk-Averse Climate
Alzheimer’s disease (AD) and AD-related dementias (ADRD) affect more than 5 million Americans and…